Efficacy and safety of ruxolitinib in ineffective erythropoiesis suppression as a pretransplantation treatment for pediatric patients with beta‐thalassemia major
Pediatric Blood & Cancer2021Vol. 68(11), pp. e29338–e29338
Citations Over Time
Galina Ovsyannikova, Dmitry Balashov, I. A. Demina, Larisa Shelikhova, А. V. Pshonkin, Michael Maschan, G. А. Novichkova, Alexey Maschan, Н.С. Сметанина
Abstract
Ruxolitinib is promising as a short-term pre-HSCT treatment for pediatric patients with TDT and pronounced IE.
Related Papers
- → Ineffective erythropoiesis and thalassemias(2009)178 cited
- → Ineffective Erythropoiesis in β‐Thalassemia(2013)130 cited
- → Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major(2019)46 cited
- → Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia(2022)7 cited
- → Iron metabolism and ineffective erythropoiesis in β‐thalassemia mouse models(2010)20 cited